Guangdong Hec Technology Holding Company Limited (06887) has applied to the Hong Kong Stock Exchange for approval to list and trade 112.7 million H shares on the Hong Kong Stock Exchange.

Guangdong Hec Technology Holding (06887) has announced that the company has applied to the Stock Exchange for approval to list and trade 1.127 billion H shares on the Stock Exchange. The number of H shares to be issued is based on the assumption that shareholders who hold all of the HEC CJ PHARM H shares have converted them to H shares according to the exchange ratio and terms of the merger agreement, and no shares will be issued for listing by way of introduction. The H shares will be listed on the Main Board of the Stock Exchange by way of introduction, with the exception of issuance to exchanging shareholders. It is expected that the H shares will begin trading on the Stock Exchange on Thursday, August 7, 2025 at 9:00 am. Trading of H shares will be conducted in units of 100 shares per lot. The stock code for the H shares is 6887. The company has proposed a privatization plan in accordance with the Company Law of China, other applicable Chinese laws, Hong Kong legislation, the Takeovers Code, and the Listing Rules, whereby H shares will be issued to acquire the HEC CJ PHARM H shares held by exchanging shareholders in order to privatize HEC CJ PHARM through a merger. The exchange ratio for each HEC CJ PHARM H share cancelled under the privatization plan will be 0.263614 new H shares, and the corresponding number of H shares will be issued. In addition, as part of the privatization plan, once all conditions precedent and conditions are met (or waived, if applicable), HEC CJ PHARM will pay a special dividend to shareholders of HEC CJ PHARM listed on the special dividend record date, calculated at HK$1.50 per HEC CJ PHARM share. After meeting the implementation conditions and completing the privatization plan, (a) the listing status of HEC CJ PHARM on the Stock Exchange will be cancelled; (b) the company's H shares will be listed on the Stock Exchange; (c) exchanging shareholders will become shareholders; and (d) the company will assume all assets, liabilities, benefits, business, employees, contracts, and all other rights and obligations of HEC CJ PHARM, which will ultimately be cancelled in China. All domestic shares of HEC CJ PHARM held by the company (i.e., all issued domestic shares of HEC CJ PHARM) and all HEC CJ PHARM H shares held by the company and its subsidiaries will be cancelled upon completion of the merger. Once the H shares are approved for listing and trading on the Main Board of the Stock Exchange, and the company meets the share inclusion requirements of Hong Kong Settlement, the H shares will be accepted for settlement by the Hong Kong Settlement as eligible securities for deposit, settlement, and clearing within the Central Clearing System, starting from the day when the H shares begin trading on the Stock Exchange or such other date determined by the Hong Kong Settlement.